Inside Our Lab: Why Fresh, Verified Cells Matter

There is a question most patients never think to ask, and it may be the most revealing one available: where did these cells come from, and who checked them?

Much of this book has been about what stem cells do. This chapter is about something just as important and far less discussed: whether the cells a patient receives are actually alive, healthy, and capable of doing it. It is easy to assume that a stem cell is a stem cell — that as long as you are receiving “stem cell therapy,” the cells are doing their job. The reality is more demanding. Stem cells are living, fragile things. Like any living cell, they are sensitive to how they are handled — to temperature, to processing, and above all to time. From the moment cells are prepared, a clock is running. This matters enormously, because many clinics do not make their own cells. They order them, frozen, from an outside source. Those cells are shipped, stored, thawed, and administered — sometimes after a long journey, sometimes with little verification of what condition they are actually in by the time they reach the patient. Freezing and thawing alone can reduce the proportion of healthy, functional cells. And the longer cells sit after thawing, the more their quality can decline — meaningful degradation can occur within a day, and beyond that, a substantial fraction of the cells may no longer be viable at all. IN PLAIN TERMS Think of stem cells like fresh produce. Picked and eaten the same day at the source, they are at their peak. Shipped frozen across the country, thawed on a counter, and left sitting before use, they are a shadow of what they were — even if they still look the part. With living cells, freshness is not a luxury. It is the difference between delivering something vital and delivering something diminished. There is a further problem that even careful clinics run into: the standard quick test for whether cells are “alive” tends to overcount them. It catches cells that are already dead but misses cells that are in the early stages of dying — so a sample reported as highly viable may, in truth, contain far fewer fully functional cells than the number suggests. A patient, and sometimes even the provider, may never know. This is why we built our own biotechnology laboratory in-house, and why we do two things differently. First, we make our cells fresh. Because the lab is our own, the cells do not endure a long supply chain of shipping, prolonged storage, and delayed thawing before they reach you. We control the timeline from preparation to administration, which means the cells you receive are as close to their peak as possible — not a frozen product of unknown age and handling. Second, we verify what we deliver. Every patient receives a detailed flow cytometry report on the cells being administered — a precise measurement of their viability and characteristics. Flow cytometry is a laboratory technique that examines cells individually and in large numbers, giving an accurate accounting of how many are truly healthy and what they are. Rather than asking you to take our word for it, we measure it, and we show you. IN PLAIN TERMS Most people would never buy a car without knowing what is under the hood, or take a medication with no label. Yet in much of this field, patients receive cells with no real accounting of their quality. A flow cytometry report is the label — a plain statement of exactly what you are receiving. The principle underneath all of this is simple: you cannot manage, or trust, what you do not measure. Knowing the viability and quality of the cells is what separates a controlled, verifiable therapy from an act of faith. It does not guarantee any particular outcome — nothing truthful can — but it ensures that what is being delivered is real, healthy, and known, rather than assumed. There is one more layer of quality that has nothing to do with biology, and everything to do with trust: licensing. In Mexico, regenerative medicine is regulated by COFEPRIS — the Federal Commission for the Protection against Sanitary Risks — the country’s equivalent of the U.S. Food and Drug Administration. Proper COFEPRIS licensing is not a formality; it is a serious regulatory standard governing how cells may be produced and administered. Our institute is licensed by COFEPRIS for both stem cell administration and stem cell biotechnology — that is, both for treating patients and for producing the cells themselves. This dual licensing is not as common among stem cell clinics as patients tend to assume, and it matters a great deal. IN PLAIN TERMS Ask yourself a simple question: would you visit an unlicensed clinic in your own country — one operating outside the oversight of its health authorities? Of course not. The same standard should apply when you travel for care. A clinic’s licensing tells you whether it operates under genuine regulatory accountability, or outside of it. When you combine the two — cells made fresh in a licensed laboratory, and verified for quality before they are given — you have something that much of this field lacks: a therapy you can actually account for. Not a promise, but a process you can see, measure, and trust. In a field crowded with claims, that accountability is one of the most meaningful things a clinic can offer, and one of the most important things a patient can look for.